3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
34
Lymphoma, Non-Hodgkin
25
Lymphoma, Follicular
25
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Mantle-Cell
16
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Large-Cell, Immunoblastic
8
Waldenstrom Macroglobulinemia
6
Lymphoma, B-Cell
5
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia
2
Orbital lymphoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Interventions
Bendamustine Hydrochloride
3
fludarabine
2
Cyclophosphamide
2
Brentuximab Vedotin
2
pembrolizumab
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
Standard of Care
1
Rituximab
1
Radiotherapy
1
Melphalan
1
Etoposide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphatic Diseases
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts